Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

121.62 +2.38 (+2.00%)
Streaming Delayed Price Updated: 1:41 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
News headline image
Why Merck (MRK) Stock Is Falling Today
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by a... 
Via StockStory
News headline image
Gapping S&P500 stocks in Tuesday's session ↗
Curious about the market action on Tuesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Get insights into the top movers in the S&P500 index of Tuesday's pre-market session. ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Merck Tops Q4 Earnings And Revenue Estimates ↗
Merck came out with quarterly earnings of $1.72 per share. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Market Whales and Their Recent Bets on MRK Options ↗
 
Via Benzinga
News headline image
A Closer Look at Merck & Co's Options Market Dynamics ↗
 
Via Benzinga
News headline image
Forecasting The Future: 12 Analyst Projections For Merck & Co ↗
 
Via Benzinga
News headline image
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook ↗
Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact. 
Via Benzinga
News headline image
PayPal, Estée Lauder, UBS And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops
Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.8% year on year to $15.62 billion. On the other hand, the company’s... 
Via StockStory
News headline image
Merck Tops Q4 Forecasts, But Dow Jones Giant Dives On 2025 Guidance ↗
Merck topped Wall Street's Q4 expectations Tuesday, but the stock is taking a hit on light guidance. 
Via Investor's Business Daily
Topics Stocks
News headline image
Merck Vs. Pfizer: Which Pharmaceutical Giant Will Prevail In Q4 Earnings? ↗
Merck and Pfizer are heading into fourth quarter earnings with different technical setups, leaving investors unsure of which stock will prevail. While Merck shows short-term strength, Pfizer is... 
Via Benzinga
News headline image
Balancing Dividends and Fundamentals: The Case of NYSE:MRK. ↗
Exploring MERCK & CO. INC. (NYSE:MRK)'s dividend characteristics. 
Via Chartmill
News headline image
Why This Beaten-Down Stock Is a Buy in 2025 and Beyond ↗
Via The Motley Fool
News headline image
NYSE:MRK is probably undervalued for the fundamentals it is displaying. ↗
MERCK & CO. INC. (NYSE:MRK) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Earnings Scheduled For February 4, 2025 ↗
 
Via Benzinga
News headline image
The Dogs Of The Dow 2025 ↗
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts ↗
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure. 
Via Benzinga
News headline image
5 Top Stocks to Buy in February 2025 ↗
All of them have great upside. 
Via The Motley Fool
News headline image
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders ↗
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
News headline image
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings ↗
The Senate will meet Wednesday to start the confirmation hearing process for Robert F. Kennedy Jr. 
Via Investor's Business Daily
News headline image
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024 ↗
Via The Motley Fool
Topics Stocks
News headline image
Merck/Eisai's Keytruda Plus Lenvima Regime Shows Mixed Data In Esophagus Cancer Study ↗
Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment. 
Via Benzinga
News headline image
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots ↗
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
News headline image
RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing ↗
Robert F. Kennedy Jr., HHS secretary nominee, faces criticism for financial ties to vaccine lawsuits, raising ethical concerns over regulatory impartiality. 
Via Benzinga
Topics Lawsuit
News headline image
3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35% ↗
Via The Motley Fool
News headline image
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside ↗
Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target. 
Via Benzinga
News headline image
Moderna Surges After Larry Ellison Calls Out The Potential Of AI In Cancer Vaccines ↗
Ellison, Oracle's chairman, pointed to the use of AI to develop drugs like Moderna's cancer vaccine. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Why Summit Therapeutics Stock Is Jumping Today ↗
Via The Motley Fool
News headline image
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? ↗
Via The Motley Fool
Topics Stocks
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.